#United States #New York #Class Action #Levi Korsinsky #Embecta Corp.

Embecta Corp. Class Action Lawsuit: What You Need to Know

In a significant development for shareholders of Embecta Corp. (NASDAQ: EMBC), a class action lawsuit has been filed amidst alarming reports of revenue misrepresentation that led to a sharp decline in the company’s stock value. This situation has put many investors in a precarious position as they scramble to recover their losses arising from the drastic drop in share prices.

Background of the Case

On July 15, 2026, it was revealed that Embecta’s shares plummeted from $9.25 to $3.90—a staggering 57.8% drop—prompted by a massive $75 million reduction in revenue guidance. This cut was significantly influenced by weaknesses in the U.S. pen needle segment, which constitutes about 85% of Embecta’s product portfolio. The company had maintained optimistic revenue projections throughout the fiscal year 2026, leading investors to believe in its profitability while internally struggling with share losses and declining sales volumes.

The allegations put forth in the lawsuit claim that while management was aware of their declining pen needle sales, they continued to provide misleading revenue guidance, thus violating their duty to shareholders and contributing to the financial losses experienced by investors. The class action is aimed at those who purchased shares between November 25, 2025, and May 4, 2026.

Revenue Impact and Allegations

The primary concerns outlined in the lawsuit emphasize that shortcomings in the pen needle category had a disproportionate impact on the company's overall sales performance, accounting for more than 70% of the revenue miss. Specific allegations include:

• - Misleading Statements: Management described the pen needle segment as “incredibly resolute” shortly before the guidance miss, failing to disclose the extent of their struggles with a crucial customer.
• - Market Volume Weakness: Issues such as reduced demand in retail channels for insulin delivery products contributed approximately $20 million to the decline in forecasted revenues.
• - Shifts to Lower-Cost Alternatives: Many patients have begun purchasing from less expensive channels where Embecta does not compete, putting additional strain on reported sales.
• - Inventory and Pricing Pressures: Additional factors like inventory reductions at certain outlets and pricing pressures contributed another $8 million to the financial setbacks faced by the company.

What Investors Should Do

For shareholders who believe they may have been impacted financially, it’s crucial to evaluate their eligibility to join the lawsuit. The firm Levi & Korsinsky, which is leading the legal action, encourages affected investors to act quickly. The deadline for applications to serve as lead plaintiffs is August 17, 2026.

Investors interested in participating need to gather documentation related to their stock purchases, including trade confirmations that show purchase dates and quantities. Even those who no longer hold their shares but suffered losses during the class period are eligible to join the action.

Legal Process and Expectations

Participating in a class action lawsuit poses no upfront costs for investors. These lawsuits are typically handled on a contingency basis, meaning expenses are only incurred if the case is successful. While the timeline for resolution can take several years—usually ranging from two to four—it provides a pathway for shareholders to potentially recover their losses.

Joseph E. Levi, the attorney leading the case, commented on the importance of revenue guidance disclosure obligations within the medical device sector, particularly given the current market dynamics and how they have affected investors’ trust.

For those interested in learning more or joining the class action suit, Levi & Korsinsky is available for consultations over the phone or via email. Immediate action can help ensure that investors maintain their rights as aggrieved shareholders in this ongoing legal battle.

• ---

For more information, investors can contact Joseph E. Levi at (212) 363-7500 or [email protected].